[The postgraduate training of clinician interns in a department of polyclinical therapy].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to V S Kosheleva.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Simultaneous study of renin activity and aldosterone concentration in the blood plasma of 180 out-patients with hypertensive disease has shown that persons with normal or increased reninemia predominate in the I stage of disease. Moderate positive correlation was observed between the level of aldosterone and renin activity; aldosterone-renin index at the stage of the disease remains unchanged. In stage II of hypertensive disease renin activity diminishes and the concentration of aldosterone in blood plasma rises, aldosteronerenin index is enhanced at the expense of aldosterone predominance, which is most often seen in the sub-group of patients with low reninemia. Aldosterone-renin index correlates positively with the duration of hypertensive disease.
Simultaneous study of renin activity in plasma of peripheral blood and values of central and renal hemodynamics in 180 patients with hypertensive disease showed no significant differences in the hemodynamic values in patients with stage I of the disease which differed in the activity of blood plasma renin. No dependence of the volume of circulating blood on the type of reninemia was revealed in stage II, but a significant decrease in the coefficient of circulation effectiveness and in cardiac output and an increase in peripheral vascular resistance were disclosed in patients with low renin activity in blood plasma. Diminished effective renal blood flow and increased renal vascular resistance and filtration fraction were the most marked findings in patients with high renin activity. The changes in renal hemodynamics may be associated with the effect of intrarenal angiotensin II.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.